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Expression of Protein Kinase C b in the Heart Causes Hypertrophy in Adult Mice
and Sudden Death in Neonates
Joel C. Bowman,* Susan F. Steinberg,‡§ Tiangrong Jiang,‡ David L. Geenen,* Glenn I. Fishman,* and Peter M. Buttrick*
*Section of Molecular Cardiology and Department of Medicine, Albert Einstein College of Medicine, New York 10461; and ‡Department
of Pharmacology and §Department of Medicine, Columbia University, New York 10032

Abstract
Protein kinase C (PKC) activation in the heart has been
linked to a hypertrophic phenotype and to processes that influence contractile function. To establish whether PKC activation is sufficient to induce an abnormal phenotype, PKCb
was conditionally expressed in cardiomyocytes of transgenic mice. Transgene expression in adults caused mild and
progressive ventricular hypertrophy associated with impaired diastolic relaxation, whereas expression in newborns
caused sudden death associated with marked abnormalities
in the regulation of intracellular calcium. Thus, the PKC
signaling pathway in cardiocytes has different effects depending on the timing of expression and, in the adult, is sufficient to induce pathologic hypertrophy. (J. Clin. Invest.
1997. 100:2189–2195.) Key words: cardiac hypertrophy • protein kinase C • calcium handling • conditional transgenic

Introduction
Protein kinase C (PKC)1 comprises a family of serine/threonine kinases that influence a variety of cellular functions. In
ventricular cardiocytes, specific isoforms are activated by a
number of putative hypertrophic stimuli, including a1-adrenergic agonists (1, 2), mechanical stretch (3, 4), angiotensin II (5),
and endothelin (6, 7). Intracellular PKC phosphorylation targets include proteins in the sarcolemma and sarcoplasmic
reticulum that regulate calcium homeostasis as well as sarcomeric proteins that influence the calcium sensitivity of the contractile machinery (8–12). In addition, PKC has been implicated in the modulation of cardiac gene expression and in the
induction of cardiac hypertrophy (13–15). While there has
been progress towards identifying specific PKC isoform functions in cultured cells, a direct link between enzyme activation
and altered myocyte function in the in vivo context has not
been established.
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To address this, we have developed a binary transgenic
mouse model in which a constitutively active PKCb isoform
can be conditionally expressed in the heart. Transient transfection of cultured cardiocytes with this same construct results in
transcriptional transactivation of genes, atrial natriuretic factor
(ANF), and b myosin heavy chain, which are characteristically
activated in pathologic cardiac hypertrophy (16–18). In addition, abnormal expression of PKCb has been described in the
hearts of animals and humans subjected to pathologic loads
during postnatal life (19, 20), although this remains controversial. These lines of evidence suggest but do not establish a
causal link between kinase activation and cardiac adaptation.

Methods
Animal model. The salient features of the model are shown in Fig.
1 A. Two lines of mice were generated using standard techniques in a
C57/Bl6 background. Cardiac myocyte specificity in one line is determined by a gene in which z 2.9 kb of 59 flanking sequence from the
rat a myosin heavy chain gene drives expression of the tetracyclinecontrolled transactivator (tTA) (21–23). In the second line, the target
gene, under the control of a heptamerized tetracycline operator/CMV
minimal promoter, is a bovine PKCb rendered constitutively active
by an internal deletion (aa 6–159) which includes the pseudosubstrate
and a portion of the C1 domains of the intact molecule (24). The general strategy and the construct backbones have been described in detail previously (23). The genotype of the offspring was determined either by PCR (primers are shown below) or Southern blotting using
standard techniques.
Animals were crossed and subsequently were either maintained
on tetracycline (1 mg/ml in drinking water supplemented with 1% sucrose) or were given no drug. To suppress neonatal gene expression,
tetracycline was administered to pregnant animals throughout gestation.
Physiologic measurements. To assay in vivo hemodynamics, animals were anesthetized with isofluorene and intubated. A PE-10 fluidfilled cannula attached to a pressure transducer (Statham Instruments,
Hato Rey, PR) was advanced into the right carotid artery to determine baseline arterial pressures. Subsequently the chest was opened
and a 2F micromanometer transducer (SPR-407; Millar Instruments,
Inc., Houston, TX) was inserted through the apex of the left ventricle
for the simultaneous determination of left ventricular pressure. A bolus infusion of isoproterenol (0.1 ml of a 1027 M solution) was then
administered via the femoral vein while left ventricular pressure was
monitored.
Echocardiograms were obtained on anesthetized mice using a 7.5
MHz transducer (Hewlett Packard, Andover, MA). Left ventricular
end systolic and end diastolic dimensions and ejection fractions were
calculated from 2D directional M-mode tracings.
Analytic techniques. RNA was purified from the hearts of binary
adult animals using Trizol Reagent (GIBCO BRL, Gaithersburg,
MD). RT-PCR was performed on RNA according to standard techniques (Gene Amp RNA PCR kit; Perkin Elmer Corp., Norwalk,
CT). Primers for the PKCb transgene (which flank the internal deletion) were: sense, 59-ATGGCTGACCCGGCCG; antisense, 59-CTAAATGTTTCGTTCCACTCGGGG, and for the tTA transgene
(which recognize the transcriptional initiation site of the a myosin
Expression of PKCb in the Heart
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Figure 1. (A) Schematic
illustration of the binary
transgenic system used.
The transactivator mouse
expressed the tTA chimeric protein under the
control of z 2.9 kb of the
rat a myosin heavy chain
promoter, whereas the
target mouse harbored a
constitutively active form
of the bovine PKCb gene
downstream of the tTA
responsive promoter. (B)
Reverse transcriptase
PCR on cardiac tissue
from binary transgenic
animals maintained on or
off tetracycline. Lanes
1–5 represent hearts
from individual animals
harboring both transgenes but not treated with
tetracycline, whereas
lanes 6–9 represent hearts
from animals with an
equivalent genotype but
maintained on tetracycline. PKCb mRNA (282
bp) expression was only
seen in untreated animals. A lane showing molecular weight markers
(M) and a PCR positive
control (1) are also
shown.

heavy chain gene and the splice acceptor region): sense, 59-TCAGACCGAGATTTCTCCATCCC; antisense, 59-CGATCAAAGGACTCTGGTA. Amplification was done for 30 cycles and the annealing
temperature was 518C. Products were electrophoresed on 2% agarose
gels and the amplified bands were visualized by ethidium bromide
staining.
RNA was run on formaldehyde denaturing gels and blotted using
standard techniques. After cross-linking, the filters were hybridized
using QuikHyb (Stratagene, La Jolla, CA), and exposed to film. cDNA
probes for the human slow sarcoplasmic reticular calcium-dependent
ATPase (SERCA2) and mouse atrial natriuretic peptide (ANF) were
provided by D. MacLennon (University of Toronto, Toronto, Canada)
and J. Seidman (Harvard Medical School, Boston, MA), respectively.
An oligonucleotide complementary to sequence within the 39 untranslated region of the mouse b myosin heavy chain gene was used,
59-TGTTGCAAAGGCTCCAGGTCTGAGGGCTTC.
Cardiac muscle homogenates were extracted and immunoblotted
according to previously published methods (25). The antibody for
PKCe was from D. Fabbro (Ciba-Geigy, Basel, Switzerland).
Myofibrillar ATPase assays on murine heart protein were performed as previously described (26).
Histologic assessment was done on 5 mM formalin-fixed paraffinembedded sections stained with hematoxylin and eosin according to
standard techniques. The tissue sections were subjectively evaluated
by an experienced pathologist blinded as to animal genotype.
Intracellular calcium transient measurements. To isolate cardiocytes from neonatal hearts, the tissue was initially washed in a dissociation solution containing (mM): NaCl 110, KCl 5.4, NaHCO3 4, MgCl2
1.6, NaH2PO4 1.8, Hepes 20, glucose 5, l-glutamine 4, taurine 10. The
2190
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muscle was then minced and bathed in the dissociation solution containing 3 mg/ml trypsin and 5 mg/ml BSA and shaken in a 378C water
bath for 15 min. Five successive digestion–trituration cycles were carried out. The supernatant from the first was discarded and those from
the subsequent cycles were pooled and centrifuged. The pelleted cells
were resuspended in dissociation solution containing 5 mg/ml BSA.
Cells were analyzed within 5 h of preparation. The method for Fura-2
loading and measurement of calcium transients in neonatal cardiocytes has been described previously (27). Cells were isolated from the
hearts of six binary PKC/tTA and five single PKC transgenic animals.
The investigator performing the analysis was unaware of the genotype of the animals.
Statistical analysis. Unless specifically noted, statistical differences among groups were determined by ANOVA, followed by a
Newman-Keul’s posthoc analysis. Survival data were analyzed using
the x2 statistic (28). Significance is reported at the 0.05 level.

Results
PKCb expression in animals harboring both transgenes should
be regulated by the absence or presence of exogenous tetracycline and should be restricted to the cardiomyocytes. Data
demonstrating the fidelity of the binary system are illustrated
in Fig. 1 B and demonstrate regulated expression of the PKCb
gene in hearts from animals harboring both genes. The transgene is expressed only in binary animals maintained in an unsuppressed state, that is, off tetracycline.
To evaluate the effects of PKCb overexpression, crosses

Table I. Heart and Body Weights in Animals Off Tetracycline
for 9 mo (by Gender)
Genotype

n

Gender

Heart wt

Body wt

Table II. Heart and Body Weights and Left Ventricular
Dimensions in Animals Off Tetracycline for 5 mo

Heart/ Body wt
Genotype

Binary
Single
Binary
Single

5
3
3
6

Male
Male
Female
Female

mg

g

193612*
15565
145617*
120618

3261
3562
2862
2661

Tet

n

Body wt

Heart/
Body wt

LVEDD

LVESD

FxShort

g

mg/g

mm

mm

%

2564
2765
3166
3367*

4.560.2*‡
3.860.2
3.860.3
3.760.2

3.660.2
3.560.3
3.660.4
3.660.1

1.560.3
1.660.2
1.460.2
1.560.2

5469
5568
6264
5566

mg/g

5.6860.37*
4.4360.41
5.1460.51‡
4.5160.25

Data are mean6SEM. Binary animals harbor both the tTA and the
PKCb transgenes, whereas single animals harbor only the PKCb transgene. * P , 0.05 and ‡ P , 0.07 versus gender-matched single transgenics.

between animals homozygous for the PKCb transgene and heterozygous for the tTA transgene were made (50% of the offspring would be predicted to harbor both transgenes and 50%
to harbor only PKCb). Animals were maintained on tetracycline throughout gestation and through early postnatal life. At
8–10 wk of age the drug was discontinued in half of the animals. A cohort of animals was killed 4 wk after randomization.
A second cohort of animals was maintained for 5 mo and in
situ cardiac dimensions and performance were evaluated. In a

Binary
Single
Binary
Single

Off
Off
On
On

5
5
5
4

Data are mean6SD. Animals were maintained on tetracycline (Tet) until 8–10 wk of age at which point half were taken off the antibiotic. Animals were killed and measurements were made 5 mo later. *P , 0.05 vs.
single/off; ‡ P , 0.05 vs. binary/on. LVEDD, Left ventricular diastolic
dimension; LVESD, left ventricular end systolic dimension; FxShort,
fractional shortening.

third group, the antibiotic was discontinued in all animals at
8 wk and the animals were subsequently maintained off tetracycline for 9 mo. None died spontaneously. The animals were
killed at the various time points mentioned. Heart and body
weight comparisons were made in all groups and the animals
at the 5-mo time point underwent a more complete physiologic
evaluation.

Figure 2. Representative hematoxylin and eosin–stained sections from 7-mo-old adult mouse hearts. A is a section from an animal harboring
only the PKCb transgene and B is from a binary (PKCb and tTA) animal. The binary animal evidences mild cellular hypertrophy and no evidence of interstitial fibrosis or cellular necrosis.
Expression of PKCb in the Heart
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Table III. Hemodynamics before and after Isoproterenol Infusion
HR
Genotype

Tet

Binary
Single
Binary
Single

Off
Off
On
On

BP

LVP

Closed chest

220669
240610
200617
218645

9766
90610
93612
99618

1dP/dt

2dP/dt

LVP

Open chest, before isoproterenol

78623
91612
9863
91615

14696399
18276247
1766668
16986231

13736479*
18446401
18376175
16826383

1dP/dt

2dP/dt

Open chest, after isoproterenol

92613*‡
133640
115623
138615

16036370*
21036415
18466157
18916196

15646272*‡
25356686
22346286
24166511

Data are mean6SD. *P , 0.05 vs. single/off; ‡ P , 0.05 vs. single/on. Animals (and n) are exactly the same as those shown in Table II. Tet, Tetracycline; HR, heart rate; LVP, left ventricular pressure.

9 mo after cessation of tetracycline, the binary animals had
a significant increase both in heart weight and in heart/body
weight ratio (Table I). There was a trend for this increase to be
more marked in males (25% increase in heart weight and 28%
increase in heart/body weight ratio) than in females (21% increase in heart weight and 14% increase in heart/body weight
ratio), although this gender difference did not reach statistical
significance. This increase in heart size was gradual: in the group
killed 4 wk after randomization, the binary animals off tetracycline had a slight (5%) increase in heart/body weight ratio
which was not statistically distinct from the matched tetracycline-treated control groups (P , 0.08 versus single PKCb
transgenic animals maintained on tetracycline). 5 mo after randomization, the heart/body weight ratios in the binary animals
off tetracycline were increased by z 20% over the single transgenic animals (Table II, P , 0.05 vs. other groups). In contrast,
there was no increase in this ratio in the binary animals maintained on tetracycline relative to their matched controls. In
contrast to the data shown in Table I, half of the binary and
single transgenic animals at this time point were maintained on
the antibiotic to control for any unanticipated effects of tetracycline or sucrose on cardiac physiology or patterns of gene expression. The increase in body weight seen in these treated animals likely reflects the sucrose added to the drinking water.
However, absolute heart weight was significantly increased by
11% in the untreated binary animals relative to the untreated
single transgenic group (113 vs. 102 mg, P , 0.05). The increase in heart weight was not accompanied by significant
changes in internal left ventricular systolic or diastolic dimensions determined by echocardiography, consistent with concentric left ventricular hypertrophy. Ejection fraction did not

differ among groups, which is not surprising as this is a relatively insensitive, load-dependent measure of systolic function
and the predominant defect in the hearts of the PKCb expressing mice appears to be diastolic (see below). Histologic evaluation (Fig. 2) confirmed the presence of mild myocyte hypertrophy and did not show any significant intercurrent pathology.
Conventional molecular markers of cardiac hypertrophy, an
increase in mRNA levels of ANF and b myosin heavy chain
and a decrease in SERCA2, were not seen and compensatory
changes in the abundance of PKC were not evident. In addition, calcium-dependent myofibrillar ATPase curves did not
differ between single and binary off-tetracycline animals.
The carotid arteries and left ventricles of the same adult
mice identified in Table II were cannulated and pressures before and after isoproterenol infusions were determined (Table
III and Fig. 3). Closed chest arterial pressures did not differ
among groups; however, open chest peak left ventricular pressure and (2) dP/dtmax were depressed at baseline and this was
accentuated (and dP/dtmax was also reduced) in response to an
inotropic challenge with isoproterenol.
To assess the effects of transgene expression in early postnatal life, tetracycline was discontinued at midgestation. Survival data from heterozygote tTA/PKC crosses are shown in
Fig. 4 (one in four would be predicted to harbor both transgenes). While animals maintained on tetracycline showed
no mortality (42/42 live births survived until adulthood), 16/65
(z 25%) of the untreated animals died within the first 3 wk of
life. Death was sudden and not heralded by evidence of intercurrent disease. The time course is consistent with gene expression driven by the a myosin heavy chain promoter (29,
30). The genotype of the off-tetracycline survivors was (PKCb/

Figure 3. Representative pressure tracings
(mmHg) from a binary
transgenic either on (A)
or off (B) tetracycline.
The first panel in each
composite shows closed
chest arterial pressure,
the second shows simultaneous left ventricular and
aortic pressure (open
chest), and the third
shows left ventricular
pressure after bolus infusion of isoproterenol.
2192
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Figure 4. Survival curves of heterozygote crosses indicating that
z 25% of live births off tetracycline (dotted line) and none of those
on tetracycline (solid line) died over the first 3 wk of life.

tTA): 1/1 5 3; 2/1 5 19; 1/2 5 12; 2/2 5 15 (P , 0.02 by
x2 analysis). These facts strongly suggest that expression of the
constitutively active PKCb during the early postnatal period is
lethal. A second line of PKCb animals was also crossed with
the tTA transactivator mice and showed a similar disproportionate loss of binary animals in early postnatal life (0/12 animals from these crosses surviving to adulthood were binary
transgenic animals).
Since the cause of death in the binary transgenic animals
was presumed to be arrhythmic, myocytes were isolated from
5–8-d-old binary (tTA/PKC) or single (PKC) untreated animals and their ability to regulate intracellular calcium was compared. There were no obvious microscopic differences in the
size of the cells isolated from these animals. The cells were
loaded with Fura-2 and calcium transients were monitored
over a range of stimulation rates (Fig. 5 B). Cardiocytes from
both groups show the typical rate-dependent increase in the
amplitude and decrease in the duration of the calcium tran-

Figure 5. (A) Representative calcium transients from a PKCb expressing and nonexpressing myocyte (tTA/PKCb: 1/1 and 2/1). (B) At each
stimulation rate, a series of six electrically driven calcium transients at steady state was signal averaged for analysis of the amplitude and duration
at half-maximal amplitude of the calcium transient. Results of calcium measurements in 47 PKCb overexpressing and 37 nonexpressing cells are
summarized (*P , 0.05 vs. matched values). (C) A representative record of typical calcium oscillations near the peak systolic value in control
(top) and PKCb overexpressing myocytes (bottom).
Expression of PKCb in the Heart
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sient. However, the increase in amplitude was significantly attenuated in myocytes from the binary animals at the most
rapid pacing rate and the duration was prolonged in these myocytes at all pacing rates. The defect in the kinetics of relaxation
of the calcium transient led to secondary spikes that delayed
the return of intracellular calcium to baseline diastolic levels in
55% of cells from the binary animals (Fig. 5 C) and in none of
the cells from the single transgenic animals. In 19% of cells,
these ionic perturbations lasted for . 10 s.

Discussion
Two major questions are addressed by this study. The first is
whether expression of a single PKC isoform in the adult heart
is sufficient to effect a cardiac hypertrophic response and the
second is whether developmental context influences the physiologic impact of gene expression. The use of the binary transgenic approach for conditional gene expression is ideally suited
to answer these questions since genes can be effectively targeted to a specific cell type and expression can be temporally
defined. Previous studies using the binary system as well as
work from other laboratories using the same promoter indicate that the level of cardiocyte protein expression varies
widely throughout the heart and may be at the limits of detection in as many as 40–50% of cells (31–33). In fact, we were unable to consistently detect PKCb protein expression in binary,
unsuppressed animals although we were able to detect mRNA.
These facts probably make this general approach impractical
for the manipulation of structural genes but it appears to be
well suited to modulated expression of regulatory enzymes,
such as PKC.
The fact that neonatal and adult cardiocytes manifest very
different responses to overexpression of the PKCb gene is not
surprising, although it suggests that extrapolation of data acquired in fetal and neonatal cardiocytes to the adult heart must
be done with caution. Both PKC abundance and isoform distribution as well as the downstream components of the signaling pathways activated by PKC are different in neonatal and
adult ventricular myocytes and it is also likely that different
transcription factors predominate in the different contexts (25,
34–36). In addition, it is quite possible that the activity of the
a myosin heavy chain promoter which drives expression of the
PKC transgene varies from neonatal to adult life. Beyond this,
and likely quite relevant to the phenotypes seen in our study,
there are marked developmental differences in the dominant
mechanisms that regulate calcium homeostasis. Relaxation of
the calcium transient in adult cardiocytes is largely accomplished by reuptake by the sarcoplasmic reticulum, whereas
the neonatal cardiocyte, which has a structurally and functionally immature sarcoplasmic reticulum, relies upon the sarcolemmal Na1/Ca21 exchanger to extrude calcium during the
relaxation phase of the cardiac cycle (37, 38).
Our results suggest that sustained activation of PKC in the
absence of other intercurrent stimuli is sufficient to induce
concentric cardiac hypertrophy associated with a reduced velocity of sarcomeric relaxation. The adaptation occurs, at least
at the stage at which mild ventricular hypertrophy is evident,
without demonstrable changes in ANF, b myosin heavy chain,
or SERCA2 mRNA expression nor with changes in sarcomeric protein isoforms that would alter the calcium sensitivity
of the myofibril, demonstrating that these particular alterations (all of which have been described in other models of
2194
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cardiac hypertrophy) are not necessary for the development of
a hypertrophic phenotype. A previous transgenic model, in
which p21ras was overexpressed in the postnatal heart, induced a more dramatic hypertrophic phenotype with a similar
pattern of diastolic dysfunction which was associated with
transcriptional transactivation of the late response genes (39).
The identity of the etiologic PKC target(s) is not directly answered, although the striking impairment in relaxation suggests that abnormalities in the regulation of diastolic calcium, a
well described function of PKC activation (10, 40), may contribute to the ultimate development of the cardiac adaptation.
This speculation is supported by an analysis both of genetic
models of cardiac hypertrophy (41, 42), which are characterized by alterations in the sarcomere length/tension relationship
which precede overt muscle failure, and acquired models of
cardiac hypertrophy (43–46) which manifest altered regulation
of diastolic calcium.
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